BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

...By Virginia Li, Associate Editor Since its 2016 launch, CARB-X has awarded $249.1 million across 67...
...to companies developing prophylactics, the most recent awardee being Lumen Bioscience Inc. Lumen launched its CARB-X-funded...
...picks up where CARB-X leaves off, providing funding for Phase II-ready programs combating antimicrobial resistance. Virginia Li CARB-X antibiotic...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund

...“push” mechanisms are in place for antibiotic development, including the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X...
...We have the paradoxical situation that thanks to push incentives such as those provided by CARB-X...
...nobody expects this to be a money spinner. We consulted with the Wellcome Trust, with CARB-X...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

...The fund picks up where another push funder, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), stops. CARB-X...
...companies get products targeting high-priority pathogens through preclinical and early clinical development. Since its launch, CARB-X...
...at CARB-X is that the fund takes a careful look at assets that graduate from CARB-X...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...its platform to additional indications. Seville-based Vaxdyn receives CARB-X funding Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X...
...to prevent life-threatening, drug-resistant infections including pneumonia. Vaxdyn is the first Spanish biotech to receive CARB-X...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...for inhaled antimicrobial drug Montana-based Microbion Corp. received up to $17.1 million in grants from CARB-X...
...conduct preclinical and Phase I studies of inhaled antimicrobial drug prayibismane in CF-related pulmonary infections. CARB-X...
BioCentury | Apr 29, 2020
Emerging Company Profile

Bugworks: breaking the U.S.-centric antimicrobial mold

...The biotech has also received about $10 million in grants from U.S. non-profit antibiotics accelerator CARB-X...
BioCentury | Apr 10, 2020
Politics, Policy & Law

Piloting a new course to reimbursing antibiotics

...model are still being worked out, Kevin Outterson, executive director of the non-profit antibiotics accelerator CARB-X...
BioCentury | Jan 17, 2020
Finance

The AMR crisis is solvable -- but we must act together and fast

...contributes to poor stewardship and mis-use of therapeutics. One organization addressing this is the non-profit CARB-X...
BioCentury | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

...BioVersys gets CARB-X grant for new antibiotics class BioVersys AG received a grant from CARB-X...
...protein 1 light chain 3 alpha (MAP1LC3A) (LC3A) (LC3) Staphylococcus accessory gene regulator A (S. aureus AgrA) CARB-X...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...in the U.S., EU and Japan. Oxford Drug Design gets CARB-X funding for new antibiotics CARB-X...
Items per page:
1 - 10 of 60
BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

...By Virginia Li, Associate Editor Since its 2016 launch, CARB-X has awarded $249.1 million across 67...
...to companies developing prophylactics, the most recent awardee being Lumen Bioscience Inc. Lumen launched its CARB-X-funded...
...picks up where CARB-X leaves off, providing funding for Phase II-ready programs combating antimicrobial resistance. Virginia Li CARB-X antibiotic...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund

...“push” mechanisms are in place for antibiotic development, including the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X...
...We have the paradoxical situation that thanks to push incentives such as those provided by CARB-X...
...nobody expects this to be a money spinner. We consulted with the Wellcome Trust, with CARB-X...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

...The fund picks up where another push funder, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), stops. CARB-X...
...companies get products targeting high-priority pathogens through preclinical and early clinical development. Since its launch, CARB-X...
...at CARB-X is that the fund takes a careful look at assets that graduate from CARB-X...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...its platform to additional indications. Seville-based Vaxdyn receives CARB-X funding Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X...
...to prevent life-threatening, drug-resistant infections including pneumonia. Vaxdyn is the first Spanish biotech to receive CARB-X...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...for inhaled antimicrobial drug Montana-based Microbion Corp. received up to $17.1 million in grants from CARB-X...
...conduct preclinical and Phase I studies of inhaled antimicrobial drug prayibismane in CF-related pulmonary infections. CARB-X...
BioCentury | Apr 29, 2020
Emerging Company Profile

Bugworks: breaking the U.S.-centric antimicrobial mold

...The biotech has also received about $10 million in grants from U.S. non-profit antibiotics accelerator CARB-X...
BioCentury | Apr 10, 2020
Politics, Policy & Law

Piloting a new course to reimbursing antibiotics

...model are still being worked out, Kevin Outterson, executive director of the non-profit antibiotics accelerator CARB-X...
BioCentury | Jan 17, 2020
Finance

The AMR crisis is solvable -- but we must act together and fast

...contributes to poor stewardship and mis-use of therapeutics. One organization addressing this is the non-profit CARB-X...
BioCentury | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

...BioVersys gets CARB-X grant for new antibiotics class BioVersys AG received a grant from CARB-X...
...protein 1 light chain 3 alpha (MAP1LC3A) (LC3A) (LC3) Staphylococcus accessory gene regulator A (S. aureus AgrA) CARB-X...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...in the U.S., EU and Japan. Oxford Drug Design gets CARB-X funding for new antibiotics CARB-X...
Items per page:
1 - 10 of 60